These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35196927)

  • 1. The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.
    Tur C; Dubessy AL; Otero-Romero S; Amato MP; Derfuss T; Di Pauli F; Iacobaeus E; Mycko M; Abboud H; Achiron A; Bellinvia A; Boyko A; Casanova JL; Clifford D; Dobson R; Farez MF; Filippi M; Fitzgerald KC; Fonderico M; Gouider R; Hacohen Y; Hellwig K; Hemmer B; Kappos L; Ladeira F; Lebrun-Frénay C; Louapre C; Magyari M; Mehling M; Oreja-Guevara C; Pandit L; Papeix C; Piehl F; Portaccio E; Ruiz-Camps I; Selmaj K; Simpson-Yap S; Siva A; Sorensen PS; Sormani MP; Trojano M; Vaknin-Dembinsky A; Vukusic S; Weinshenker B; Wiendl H; Winkelmann A; Zuluaga Rodas MI; Tintoré M; Stankoff B
    Mult Scler; 2022 Aug; 28(9):1424-1456. PubMed ID: 35196927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of mental health, knowledge, and attitude of patients with multiple sclerosis and neuromyelitis optica spectrum disorder in response to 2019 novel coronavirus.
    Shaygannejad V; Afshari-Safavi A; Hatef B
    Neurol Sci; 2021 Jul; 42(7):2891-2901. PubMed ID: 33219424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
    Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
    J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown.
    Zrzavy T; Wimmer I; Rommer PS; Berger T
    Eur J Neurol; 2021 Oct; 28(10):3503-3516. PubMed ID: 33090599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review.
    Sharifian-Dorche M; Sahraian MA; Fadda G; Osherov M; Sharifian-Dorche A; Karaminia M; Saveriano AW; La Piana R; Antel JP; Giacomini PS
    Mult Scler Relat Disord; 2021 May; 50():102800. PubMed ID: 33578206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Disease Modifying Treatment, Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Vaccination on Coronavirus Disease 2019 Risk and Outcome in Multiple Sclerosis and Neuromyelitis Optica.
    Eisler JJ; Disanto G; Sacco R; Zecca C; Gobbi C
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
    Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis.
    Kong L; Wang X; Chen H; Shi Z; Lang Y; Zhang Y; Zhou H
    Mult Scler Relat Disord; 2022 Dec; 68():104167. PubMed ID: 36170773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.
    Smith TE; Kister I
    Curr Neurol Neurosci Rep; 2021 May; 21(7):36. PubMed ID: 34009478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders.
    Apostolos-Pereira SL; Campos Ferreira L; Boaventura M; de Carvalho Sousa NA; Joca Martins G; d'Almeida JA; Pitombeira M; Silvestre Mendes L; Fukuda T; Souza Cabeça HL; Chaves Rocha L; Santos de Oliveira B; Vieira Stella CR; Lobato de Oliveira EM; de Souza Amorim L; Ferrari de Castro A; Pereira Gomes Neto A; Diogo Silva G; Bueno L; de Morais Machado M; Castello Dias-Carneiro R; Maciel Dias R; Porto Moreira A; Piccolo A; Kuntz Grzesiuk A; Muniz A; Diniz Disserol C; Ferreira Vasconcelos C; Kaimen-Maciel D; Sisterolli Diniz D; Comini-Frota E; Coronetti Rocha F; Cruz Dos Santos GA; Dadalti Fragoso Y; Sciascia do Olival G; Ruocco HH; Siqueira HH; Sato HK; Figueiredo JA; Cortoni Calia L; Teixeira Dourado ME; Scolari L; Ribeiro Soares Neto H; Melges L; Magno Gonçalves MV; Vellutini Pimentel ML; de Castro Ribeiro M; Gurrola Arambula O; Diniz da Gama P; Leite Menon R; Barbosa Thomaz R; de Rizo Morales R; Sobreira S; Machado SN; Gonsalves Jubé Ribeiro T; Coelho Santa Rita Pereira V; Maia Costa V; da Nóbrega Junior AW; Vieira Alves-Leon S; Mamprim de Morais Perin M; Donadi E; Adoni T; Gomes S; Brito Ferreira M; Callegaro D; Mendes MF; Brum D; von Glehn F;
    Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34446434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America: COVID-19 in MS and NMOSD patients in LATAM.
    Alonso R; Silva B; Garcea O; Diaz PEC; Dos Passos GR; Navarro DAR; Valle LAG; Salinas LCR; Negrotto L; Luetic G; Tkachuk VA; Míguez J; de Bedoya FHD; Goiry LG; Sánchez NER; Burgos M; Steinberg J; Balbuena ME; Alvarez PM; López PA; Ysrraelit MC; León RA; Cohen AB; Gracia F; Molina O; Casas M; Deri NH; Pappolla A; Patrucco L; Cristiano E; Tavolini D; Nadur D; Granda AMT; Weiser R; Cassará FP; Sinay V; Rodríguez CC; Lazaro LG; Menichini ML; Piedrabuena R; Escobar GO; Carrá A; Chertcoff A; Pujols BS; Vrech C; Tarulla A; Carvajal R; Mainella C; Becker J; Peeters LM; Walton C; Serena MA; Nuñez S; Rojas JI
    Mult Scler Relat Disord; 2021 Jun; 51():102886. PubMed ID: 33744758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
    ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
    Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 in MS and NMOSD: A multicentric online national survey in Chile.
    Ciampi E; Uribe-San-Martín R; Soler B; Fernández R; García P; Navarrete-Asenjo C; Tirapegui JM; Torres R; Polanco J; Suárez F; Cuello MJ; Cárcamo C
    Mult Scler Relat Disord; 2020 Oct; 45():102392. PubMed ID: 32683306
    [No Abstract]   [Full Text] [Related]  

  • 15. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
    Nakamura M; Nakashima I
    Brain Nerve; 2020 Oct; 72(10):1079-1083. PubMed ID: 33051396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
    Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
    Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
    [No Abstract]   [Full Text] [Related]  

  • 17. Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources.
    Viswanathan S
    Mult Scler Relat Disord; 2020 Sep; 44():102353. PubMed ID: 32653804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-COVID Neuromyelitis Optica Spectrum Disorder.
    Rafique S; Wasim A; Sultan T; Ahmad A
    J Coll Physicians Surg Pak; 2021 Jul; 31(7):138-140. PubMed ID: 34271816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of pediatric patients with multiple sclerosis and related disorders infected with SARS-CoV-2.
    Schreiner T; Wilson-Murphy M; Mendelt-Tillema J; Waltz M; Codden R; Benson L; Gorman M; Goyal M; Krupp L; Lotze T; Mar S; Ness J; Rensel M; Roalstad S; Rodriguez M; Rose J; Shukla N; Waubant E; Wheeler Y; Casper TC; Chitnis T
    Mult Scler; 2023 Apr; 29(4-5):576-584. PubMed ID: 36960480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and emerging therapeutics for neuromyelitis optica spectrum disorder: Relevance to the COVID-19 pandemic.
    Abboud H; Zheng C; Kar I; Chen CK; Sau C; Serra A
    Mult Scler Relat Disord; 2020 Sep; 44():102249. PubMed ID: 32526698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.